Jazz Pharmaceuticals Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$324.2M
Doctors Paid
41,687
Transactions
238,939
2024 Total
$28.3M
Payment Breakdown by Category
Research$275.1M (84.8%)
Consulting$11.3M (3.5%)
Food & Beverage$5.7M (1.7%)
Travel$4.4M (1.4%)
Royalty/License$90,789 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $275.1M | 25,457 | 84.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $22.4M | 7,270 | 6.9% |
| Consulting Fee | $11.3M | 3,144 | 3.5% |
| Food and Beverage | $5.7M | 186,624 | 1.7% |
| Travel and Lodging | $4.4M | 14,202 | 1.4% |
| Grant | $3.2M | 81 | 1.0% |
| Space rental or facility fees (teaching hospital only) | $1.6M | 381 | 0.5% |
| Charitable Contribution | $398,124 | 7 | 0.1% |
| Education | $94,447 | 1,768 | 0.0% |
| Royalty or License | $90,789 | 3 | 0.0% |
| Gift | $175.39 | 2 | 0.0% |
Payments by Type
Research
$275.1M
25,457 transactions
General
$49.1M
213,482 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED AML WITH OR WITHOUT FLT3 MUTATIONS | $30.7M | 0 | 281 |
| A PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO TO CPX351 WITH GO | $29.6M | 0 | 265 |
| A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant | $14.9M | 0 | 42 |
| CLINICAL CPX-351 INVESTIGATOR SPONSORED TRIALS | $10.6M | 0 | 53 |
| A Phase 3, Randomized, Adaptive Study Comparing the Efficacy andSafety of Defibrotide vs Best Supportive Care in the Prevention ofHepatic Veno-Occlusive Disease in Adult and Pediatric PatientsUndergoing Hematopoietic Stem Cell Transplant | $8.3M | 2 | 84 |
| A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | $7.0M | 1 | 3,824 |
| A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients | $6.6M | 0 | 63 |
| A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA | $5.6M | 7 | 841 |
| AN OPEN-LABEL STUDY OF JZP-458 (RC-P) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL) | $4.7M | 0 | 177 |
| A PHASE 3, RANDOMIZED, ADAPTIVE STUDY COMPARING THE EFFICACY AND SAFETY OF DEFIBROTIDE VS BEST SUPPORTIVE CARE IN THE PREVENTION OF HEPATIC VENO-OCCLUSIVE DISEASE IN ADULT AND PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT | $4.5M | 0 | 547 |
| A PHASE 1, SINGLE-BLIND, PARALLEL-COHORT, WITHIN-SUBJECT MULTIPLE DOSE ESCALATION STUDY TO CHARACTERIZE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CX-8998 FORMULATIONS IN HEALTHY OLDER ADULT SUBJECTS | $4.5M | 0 | 14 |
| V-FAST: A PHASE 1B MASTER TRIAL TO INVESTIGATE CPX-351 COMBINED WITH VARIOUS TARGETED AGENTS IN SUBJECTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA | $4.1M | 0 | 245 |
| A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant | $4.1M | 1 | 417 |
| SIV-JAZZ PHARMACEUTICALS STRATEGIC ALLIANCE AGREEMENT | $4.0M | 0 | 2 |
| MD ANDERSON CANCER CENTER COLLABORATIVE STUDY | $4.0M | 0 | 2 |
| A double-blind, placebo-controlled, randomized-withdrawal, multicenter study of the efficacy and safety of Xyrem with an open-label pharmacokinetic evaluation and safety extension in pediatric subjects with narcolepsy with cataplexy | $3.6M | 1 | 101 |
| A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of Xyrem with an Open-Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects with Narcolepsy with Cataplexy | $3.6M | 0 | 76 |
| A PHASE 1B/2 TRIAL OF LURBINECTEDIN PLUS DOXORUBICIN IN LEIOMYOSARCOMA | $3.5M | 0 | 25 |
| A PILOT STUDY TO DETERMINE THE SAFETY OF DEFIBROTIDE IN CHILDREN WITH HIGH RISK KAWASAKI DISEASE | $3.3M | 0 | 6 |
| V-FAST: A PHASE 1B MASTER TRIAL TO INVESTIGATECPX-351 COMBINED WITH VARIOUS TARGETED AGENTS IN SUBJECTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA | $3.2M | 0 | 30 |
| A PHASE 1 TRIAL TO EVALUATE THE POTENTIAL IMPACT OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF CPX-351 (DAUNORUBICIN AND CYTARABINE) LIPOSOME FOR INJECTION TREATMENT IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES (CPX351-102) | $3.0M | 0 | 52 |
| A PHASE 1B TRIAL OF CPX-351 LOWER INTENSITY THERAPY (LIT) PLUS VENETOCLAX AS FIRST LINE TREATMENT FOR SUBJECTS WITH AML WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY | $3.0M | 0 | 204 |
| A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations | $2.9M | 0 | 296 |
| AN OPEN-LABEL STUDY OF DEFIBROTIDE FOR THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST-DISEASE (AGVHD) | $2.8M | 0 | 292 |
| A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 R-2-amino-3-phenylpropylcarbamate Hydrochloride in Subjects With Parkinson's Disease and Excessive Sleepiness | $2.7M | 6 | 706 |
| AN OPEN-LABEL MULTICENTER STUDY OF RECOMBINANT CRISANTASPASE PRODUCED IN PSEUDOMONAS FLUORESCENS (RC-P) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL) FOLLOWING HYPERSENSITIVITY TO E. COLI-DERIVED ASPARAGINASES | $2.5M | 0 | 196 |
| An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | $2.3M | 1 | 3,115 |
| A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | $2.2M | 1 | 777 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | $2.1M | 0 | 1,597 |
| A PHASE 1 TRIAL TO EVALUATE THE POTENTIAL IMPACT OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF CPX -351 (DAUNORUBICIN AND CYTARABINE) LIPOSOME FOR INJECTION TREATMENT IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES | $2.0M | 0 | 22 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Revati Shreeniwas, Md, MD | Pulmonary Disease | Stanford, CA | $1.3M | $0 |
| Dr. Haramandeep Singh, Md, MD | Sleep Medicine | San Ramon, CA | $836,885 | $0 |
| Dr. Richard Bogan, M.d, M.D | Pulmonary Disease | Columbia, SC | $781,714 | $0 |
| William Winter, Md, MD | Neurology | Charlottesville, VA | $552,384 | $0 |
| Gerard Meskill, Md, MD | Neurology | Sugar Land, TX | $539,088 | $0 |
| John Khoury, M.d, M.D | Sleep Medicine | Abington, PA | $535,087 | $0 |
| Dr. Michael Strunc, Md, MD | Sleep Medicine | Norfolk, VA | $527,549 | $0 |
| Dr. Beth Safirstein | Neurology | Hallandale Beach, FL | $512,070 | $0 |
| Dr. Mark Smith, M.d., M.b.a, M.D., M.B.A | Internal Medicine | San Francisco, CA | $504,240 | $0 |
| Nancy Lynch, M.d, M.D | Hand Surgery | San Mateo, CA | $481,539 | $0 |
| Dr. Asim Roy, M.d, M.D | Sleep Medicine | Dublin, OH | $436,169 | $0 |
| Dr. Scott Howard, Md, MD | Pediatric Hematology-Oncology | Memphis, TN | $416,648 | $0 |
| Dr. James Roy, M.d., Ph.d, M.D., PH.D | Internal Medicine | Huntsville, AL | $390,734 | $0 |
| Kenneth Cooke, Md, MD | Pediatrics | Baltimore, MD | $369,534 | $0 |
| Logan Schneider, M.d, M.D | Internal Medicine | Stanford, CA | $352,432 | $0 |
| Bruce Corser, Md, MD | Sleep Medicine | Cincinnati, OH | $347,327 | $0 |
| Vikas Jain, Md, MD | Sleep Medicine | Frisco, TX | $345,052 | $0 |
| Dr. Todd Swick, Md, MD | Neurology | Houston, TX | $341,334 | $0 |
| Dr. Edward Mezerhane, Md, MD | Internal Medicine | Miami, FL | $335,986 | $0 |
| Dr. Mitchell Cairo, Md, MD | Pediatric Hematology-Oncology | Hawthorne, NY | $333,454 | $0 |
| Dr. Alcibiades Rodriguez, Md, MD | Neurology | New York, NY | $317,050 | $0 |
| Dr. Anne Morse, Do, DO | Neurology | Danville, PA | $312,831 | $0 |
| Usama Gergis, Md, MD | Hematology & Oncology | Allentown, PA | $312,173 | $0 |
| Hillard Lazarus, Md, MD | Hematology & Oncology | Cleveland, OH | $309,123 | $0 |
| Dr. James Mccloskey, M.d, M.D | Hematology | Hackensack, NJ | $295,263 | $0 |
Ad
Top Products
- VYXEOS $140.3M
- DEFITELIO $33.0M
Associated Products (20)
- VYXEOS $140.3M
- DEFITELIO $33.0M
- Defitelio $29.6M
- XYWAV $27.6M
- ZEPZELCA $16.1M
- Xyrem $12.2M
- SUNOSI $10.1M
- RYLAZE $9.5M
- EPIDIOLEX $9.0M
- XYREM $3.5M
- Prialt $1.6M
- Erwinaze $903,271
- JZP-441 $508,375
- ZIIHERA $207,574
- ZANIDATAMAB $101,911
- ERWINAZE $94,340
- JZP-150 $77,700
- Vyxeos $70,725
- SATIVEX $24,244
- JZP-815 $14,000
Payment Categories
- Food & Beverage $5.7M
- Consulting $11.3M
- Travel & Lodging $4.4M
- Research $275.1M
- Royalties $90,789
About Jazz Pharmaceuticals Inc.
Jazz Pharmaceuticals Inc. has made $324.2M in payments to 41,687 healthcare providers, recorded across 238,939 transactions in the CMS Open Payments database. In 2024, the company paid $28.3M. The top product by payment volume is VYXEOS ($140.3M).
Payments were distributed across 271 medical specialties. The top specialty by payment amount is Neurology ($6.7M to 3,239 doctors).
Payment categories include: Food & Beverage ($5.7M), Consulting ($11.3M), Research ($275.1M), Travel & Lodging ($4.4M), Royalties ($90,789).
Jazz Pharmaceuticals Inc. is associated with 20 products in the CMS Open Payments database, including VYXEOS, DEFITELIO, and Defitelio.